Adherex's melanoma drug earns orphan status

North Carolina-based Adherex Technologies has won orphan drug designation from the FDA for its experimental melanoma therapy ADH-1. The drug is currently in Phase IIb trials in combination with regional melphalan. Adherex is also conducting Phase I trials of ADH-1 in combination with Taxotere and Xeloda.

"Our experience to date combining ADH-1 and melphalan for the treatment of in-transit melanoma has been very encouraging," said Adherex CEO Dr. William Peters in a statement. "To continue with the rapid development of this combination, two additional centers, Lehigh Valley and H. Lee Moffitt, have joined our Phase IIb trial which is ongoing at Duke and the MD Anderson."

- here's the release for more

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.